Podcasts about Lymphoma

In this special episode, Blood editor Dr. Laura Michaelis interviews Dr. Arielle Langer and Blood Associate editor Dr. Marc Blondon for this special Maternal Health episode. In honor of the second Maternal Health compendium, both discuss their papers featured in this special collection. Featured Articles: β-Thalassemia minor is associated with high rates of worsening anemia in pregnancyLongitudinal profile of estrogen-related thrombotic biomarkers after cessation of combined hormonal contraceptivesSee the entire Maternal Health Compendium Second Edition

We grant our third Christmas Wish to Tiffany, whose husband Derrick has been dealing with heart issues for years and has recently been diagnosed with Lymphoma. Thanks to Treasure Island Resort & Casino and Holiday Station Stores. DONATE to Christmas Wish: www.kdwb.com/wish.

We grant our third Christmas Wish to Tiffany, whose husband Derrick has been dealing with heart issues for years and has recently been diagnosed with Lymphoma. Thanks to Treasure Island Resort & Casino and Holiday Station Stores. DONATE to Christmas Wish: www.kdwb.com/wish.See omnystudio.com/listener for privacy information.

To have Dr. Morse answer a question, visit: https://drmorses.tv/ask/   00:00:00 - Intro - Vaccination Study https://handcraftedbotanicalformulas.com/study-henry-ford-health-system/ 00:06:58 - Panic Attacks - Anxiety - Fear of Death  00:39:00 - Seizure 00:48:10 - Thyroid Nodules 00:56:15 - Type 2 Lymphoma 01:19:49 - Tremors - Head Pressure - Mental Health Problems - Insomnia - Depression 01:46:34 - Chronic Fatigue - Update with Eyes 00:06:58 - Panic Attacks - Anxiety - Fear of Death  I have been born with aneurysm of the interatrial septum. 00:39:00 - Seizure Do I wean off this medication? 00:48:10 - Thyroid Nodules I got scared and did a biopsy. 00:56:15 - Type 2 Lymphoma Tumor on his spine that has 'spread' into the inner spine. He's in severe pain. 01:19:49 - Tremors - Head Pressure - Mental Health Problems - Insomnia - Depression No one can understand what is happening, my brain is literally burning. 01:46:34 - Chronic Fatigue - Update with Eyes Despite a lot of change, still suffering from chronic fatigue.

Dr. Monty Pal and Dr. Jason Westin discuss the federal funding climate for cancer research and the persistent problem of drug shortages, two of the major concerns facing the oncology community in 2026. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I am your host, Dr. Monty Pal. I am a medical oncologist and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. There are always multiple challenges facing oncologists, and today, we discuss two of them that really stand out for 2026: threats to federal funding for cancer research and the persistent problem of drug shortages. I am thrilled to welcome Dr. Jason Westin, who believes that one way to meet these challenges is to get oncologists more involved in advocacy, and he will share some strategies to help us meet this moment in oncology. Dr. Westin is a professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center, but he actually wears a lot of hats within ASCO. He is a member of the Board of Directors and has also previously served as chair of ASCO's Government Relations Committee. And he is also one of the inaugural members of ASCO's Political Action Committee, or PAC. He has testified before Congress about drug shortages and many other issues. Dr. Westin, I am really excited to have you on the podcast today and dive into some of these elements that will really impact our community in 2026. Thanks so much for joining us today. Dr. Jason Westin: Thank you for having me. Dr. Monty Pal: You've had such a range of experience. I already alluded to you testifying before Congress. You've actually run for office before. You wear so many different hats. I'm used to checking my PubMed every other day and seeing a new paper out from you and your group, and you publish in the New England Journal [of Medicine] on practice-setting standards and the diseases that you treat. But you've also done all this work in the domain of advocacy. I can't imagine that balancing that is easy. What has sort of motivated you on the advocacy front? Dr. Jason Westin: Advocacy to me is another way to apply our skills and help more people than just those that you're sitting across from at the time. Clinical research, of course, is a tool to try and take what we know and apply it more broadly to people that you'll never meet. And advocacy, I think, can do the same thing, where you can have a conversation with a lawmaker, you can advocate for a position, and that hopefully will help thousands or maybe even more people down the road who you'd never get to directly interact with. And so, I think it's a force multiplier in the same way that research can be. And so, I think advocacy is a wonderful part of how doctors care for our patients. And it's something that is often difficult to know where to start, but once people get into advocacy, they can see that the power, the rewarding nature of it is attractive, and most people, once they get going, continue with that through the rest of their career. Dr. Monty Pal: So, I'll ask you to expand on that a little bit. We have a lot of our younger ASCO members listening to this podcast, folks that are just starting out their careers in clinical practice or academia. Where does that journey begin? How do you get to the point that you're testifying in front of Congress and taking on these bigger sort of stances for the oncology community? Dr. Jason Westin: Yeah, with anything in medicine and in our careers, you have to start somewhere. And often you start with baby steps before you get in front of a panel of senators or other high-profile engagement opportunities. But often the first setting for junior colleagues to be engaged is doing things – we call them "Hill Days" – but basically being involved in kind of low-stakes meetings where you're with a group of peers, some of whom have done this multiple times before, and can get engaged talking to members of representatives' offices, and doing so in a way where it's a natural conversation that you're telling a story about a patient in your clinic, or that you're telling a personal experience from a policy that impacted your ability to deliver optimal care. It sounds stressful, but once you're doing it, it's not stressful. It's actually kind of fun. And it's a way that you can get comfort and skill with a group of peers who are there and able to help you. And ASCO has a number of ways to do that, both at the federal level, there's the Hill Day where we each April have several hundred ASCO members travel to Capitol Hill. There's also state engagement that can be done, so-called visiting at home, when representatives from the U.S. Congress or from state legislators are back in district. You can meet with your own representatives on behalf of yourself, on behalf of your organization, and advocate for policies in a way that can be beneficial to your patients. But those initial meetings that are in the office often they're low stakes because you could be meeting not with the representative but with their staff. And that staff sometimes is as young or even younger than our junior colleagues. These sometimes can be people in their 20s, but they're often extremely knowledgeable, extremely approachable, and are used to dealing with people who are new to advocacy. But they actually help make decisions within the office. So it's not a waste of time. It's actually a super useful way to engage. So, it's that first step of anything in life. The activation energy is always high to do something new. But I'd encourage people who are listening to this podcast already having some level of interest about it to explore ways that they could engage more. Dr. Monty Pal: You know, I have to tell you, I'm going to riff on what you just said for a second. ASCO couldn't make it any easier, I think, for folks to participate and get involved. So, if you're listening to this and scratching your head and thinking, "Well, where do I begin? How do I actually sign on for that meeting with a local representative?" Go to the ASCO ACT Network website. And I'll actually talk to our producer, Geraldine, to make sure we've got a link to that somewhere associated with this podcast after it's published, Jason, but I actually keep that on my browser and it's super easy. I check in there every now and then and see if there's any new policy or legislation that ASCO, you know, is sort of taking a stance on, and it gives me some fodder for conversation with my local representatives too. I mean, it's just an awesome, awesome vehicle. I'm going to segue right from there right to the issues. So, you and I are both at academic centers. You know, I think this is something that really pervades academia and enters into implications for general clinical practice. There's been this, you know, massive sort of proposal for decreased funding to the NCI and to the NIH and so forth. Tell us what ASCO is doing in that regard, and tell us perhaps how our community can help. Dr. Jason Westin: We live in interesting times, and I think that may be an understatement x 100. But obviously investments in research are things that when you're at an academic center, you see and feel that as part of your daily life. Members of Congress need to be reminded of that because there's a lot of other competing interests out there besides investing in the future through research. And being an elected representative is a hard job. That is something where you have to make difficult choices to support this, and that may mean not supporting that. And there's lots of good things where our tax dollars could be spent. And so, I'm sympathetic to the idea that there's not unlimited resources. However, ASCO has done an excellent job, and ASCO members have led the charge on this, of stating what research does, what is the benefit of research, and therefore why should this matter to elected representatives, to their staff, and to those people that they're elected to serve. And ASCO has led with a targeted campaign to basically have that message be conveyed at every opportunity to elected representatives. And each year on Hill Day, one of the asks that we have is to continue to support research: the NCI, NIH, ARPA-H, these are things that are always in the asks to make sure that there's appropriate funding. But effectively playing offense by saying, "It's not just a number on a sheet of paper, this is what it means to patients. This is what it means to potentially your loved ones in the future if you are in the opposite situation where you're not on the legislative side, but you're in the office receiving a diagnosis or receiving a difficult piece of news." We only have the tools we have now because of research, and each breakthrough has been years in the making and countless hours spent funded through the engine of innovation: clinical research and translational research. And so ASCO continues to beat that drum. You mentioned earlier the ACT Network. Just to bring that back again is a very useful, very easy tool to communicate to your elected representatives. When you sign up on the ASCO ACT website, you get emails periodically, not too much, but periodically get emails of, "This is a way you can engage with your lawmakers to speak up for this." And as you said, Monty, they make it as easy as possible. You click the button, you type in your address so that it figures out who your elected representatives are, and then it will send a letter on your behalf after like five clicks to say, "I want you to support research. I want you to vote for this particular thing which is of interest to ASCO and by definition to members of ASCO." And so the ACT Network is a way that people listening can engage without having to spend hours and significant time, but just a few clicks can send that letter to a representative in Congress. And the question could be: does that matter? Does contacting your senator or your elected representative do anything? If all they're hearing is somebody else making a different argument and they're hearing over and over again from people that want investments in AI or investments in something else besides cancer research, whatever it is, they may think that there's a ground shift that people want dollars to be spent over here as opposed to at the NIH or NCI or in federally funded research. It is important to continue to express the need for federal funding for our research. And so, it really is important for folks to engage. Dr. Monty Pal: 100%. One of the things that I think is not often obvious to a lot of our listeners is where the support for clinical trials comes from. You know, you've obviously run the whole gamut of studies as have I. You know, we have our pharmaceutical company-sponsored studies, which are in a particular bucket. But I would say that there's a very important and critical subset of studies that are actually government funded, right? NCI-funded clinical trials. If you don't mind, just explain to our audience the critical nature of the work that's being done in those types of studies and if you can, maybe compare and contrast the studies that are done in that bucket versus perhaps the pharmaceutical bucket. Dr. Jason Westin: Both are critical, and we're privileged that we have pharma studies that are sponsored and federally funded clinical research. And I think that part of a healthy ecosystem for us to develop new breakthroughs has a need for both. The pharma sponsored studies are done through the lens of trying to get an approval for an agent that's of interest so that the pharma company can then turn around and use that outside of a clinical trial after an FDA approval. And so those studies are often done through the lens of getting over the finish line by showing some superiority over an existing treatment or in a new patient population. But they're done through that lens of kind of the broadest population and sometimes relatively narrow endpoints, but to get the approval so that then the drug can be widely utilized. Clinical trials done through cooperative groups are sometimes done to try and optimize that or to try and look at comparative things that may not be as attractive to pharma studies, not necessarily going for that initial approval, but the fine tuning or the looking at health outcomes or looking at ensuring that we do studies in representative populations that may not be as well identified on the pharma sponsored trials, but basically filling out the gaps in the knowledge that we didn't gain from the initial phase 3 trial that led to the approval. And so both are critical. But if we only do pharma sponsored trials, if we don't fund federally supported research and that dries up, the fear I have, and many others have, is that we're going to be lacking a lot of knowledge about the best ways to use these great new therapies, these new immune therapies, or in my team, we do a lot of clinical trials on CAR T-cell therapies. If we don't have federally funded research to do the important clinical studies, we'll be in the dark about the best ways to use these drugs, and that's going to be a terrible shame. And so we really do need to continue to support federal research. Dr. Monty Pal: Yeah, there are no softball questions on this podcast, but I think everybody would be hard pressed to think that you and I would come on here and say, "Well, no, we don't need as much money for clinical trials and NCI funding" and so forth. But I think a really challenging issue to tackle, and this is something we thought to ask you ahead of the podcast, is what to do about the general climate of, you know, whether it's academic research or clinical practice here that seems to be getting some of our colleagues thinking about moving elsewhere. I've actually talked to a couple of folks who are picking up and moving to Europe for a variety of considerations, other continents, frankly. The U.S. has always been a leader when it comes to oncology research and, one might argue, research in general. Some have the mindset these days that we're losing that footing a little bit. What's your perspective? Are you concerned about some of the trends that you're seeing? What does your crystal ball tell you? Dr. Jason Westin: I am highly concerned about this. I think as you said, the U.S. has been a leader for a long time, but it wasn't always. This is not something that's preordained that the world-leading clinical research and translational research will always be done in the United States. That is something that has been developed as an ecosystem, as an engine for innovation and for job development, new technology development, since World War II. That's something that through intentional investments in research was developed that the best and brightest around the world, if they could choose to go anywhere, you wanted them to come to work at universities and academic places within the United States. And I think, as you said, that's at risk if you begin to dry up the investment in research or if you begin to have less focus on being engaged in research in a way that is forward thinking, not just kind of maintaining what we do now or only looking at having private, for profit sponsored research. But if you don't have the investment in the basic science research and the translational research and the forward-thinking part of it, the fear is that we lose the advantage and that other countries will say, "Thank you very much," and be happy to invest in ways to their advantage. And I think as you mentioned, there are people that are beginning to look elsewhere. I don't think that it's likely that a significant population of researchers in the U.S. who are established and have careers and families – I don't think that we're going to see a mass exodus of folks. I think the real risk to me is that the younger, up-and-coming people in undergraduate or in graduate school or in medical school and are the future superstars, that they could either choose to go into a different field, so they decide not to go into what could be the latest breakthroughs for cancer patients but could be doing something in AI or something in a different field that could be attractive to them because of less uncertainty about funding streams, or they could take that job offer if it's in a different country. And I think that's the concern is it may not be a 2026 problem, but it could be a 2036 or a 2046 problem that we reap what we sow if we don't invest in the future. Dr. Monty Pal: Indeed, indeed. You know, I've had the pleasure of reviewing abstracts for some of our big international meetings, as I'm sure you've done in the past too. I see this trend where, as before, we would see the preponderance of large phase 3 clinical trials and practice setting studies being done here in the U.S., I'm seeing this emergence of China, of other countries outside of the U.S. really taking lead on these things. And it certainly concerns me. If I had to sort of gauge this particular issue, it's at the top of my list in terms of what I'm concerned about. But I also wanted to ask you, Jason, in terms of the issues that are looming over oncology from an advocacy perspective, what else really sort of keeps you up at night? Dr. Jason Westin: I'm quite concerned about the drug shortages. I think that's something that is a surprisingly evergreen problem. This is something that is on its face illogical that we're talking about the greatest engine for research in the world being the United States and the investment that we've made in drug development and the breakthroughs that have happened for patients all around the world, many of them happen in the United States, and yet we don't necessarily have access to drugs from the 1970s or 1980s that are cheap, generic, sterile, injectable drugs. This is the cisplatins and the vincristines and the fludarabine type medications which are not the sexy ones that you see the ads in the magazine or on TV at night. These are the backbone drugs for many of our curative intent regimens for pediatrics and for heme malignancies and many solid tumors. And the fact that that's continuing to be an issue is, in my opinion, a failure to address the root causes, and those are going to require legislative solutions. The root causes here are basically a race to the bottom where the economics to invest in quality manufacturing really haven't been prioritized. And so it's a race to the cheapest price, which often means you undercut your competitor, and when you don't have the money to invest in good manufacturing processes, the factory breaks down, there's no alternative, you go into shortage. And this has been going on for a couple of decades, and I don't think there's an end in sight until we get a serious solution proposed by our elected officials. That is something that bothers me in the ways where we know what we should be doing for our patients, but if we don't have the drugs, we're left to be creative in ways we shouldn't have to do to figure out a plan B when we've got curative intent therapies. And I think that's a real shame.  There's obviously a lot of other things that are concerning related to oncology, but something that I have personally had experience with when I wanted to give a patient a CAR T-cell, and we don't have a supply of fludarabine, which is a trivial drug from decades ago in terms of the technology investments in genetically modified T-cells, to not then have access to a drug that should be pennies on the dollar and available at any time you want it is almost like the Air Force investing in building the latest stealth bomber, but then forgetting to get the jet fuel in a way that they can't use it because they don't have the tools that they need. And so I think that's something that we do need to have comprehensive solutions from our elected officials. Dr. Monty Pal: Brilliantly stated. I like that analogy a lot. Let's get into the weeds for a second. What would that proposal to Congress look like? What are we trying to put in front of them to help alleviate the drug shortages? Dr. Jason Westin: We could spend a couple hours, and I know podcasts usually are not set up to do that. And so I won't go through every part. I will direct you that there have been a couple of recent publications from ASCO specifically detailing solutions, and there was a recent white paper from the Senate Finance Committee that went through some legislative solutions being explored. So Dr. Gralow, ASCO CMO, and I recently had a publication in JCO OP detailing some solutions, more in that white paper from the Senate Finance. And then there's a working group actually going through ASCO's Health Policy Committee putting together a more detailed proposal that will be published probably around the end of 2026. Very briefly, what needs to happen is for government contracts for purchasing these drugs, there needs to be an outlay for quality, meaning that if you have a manufacturing facility that is able to deliver product on time, reliably, you get a bonus in terms of your contract. And that changes the model to prioritize the quality component of manufacturing. Without that, there's no reason to invest in maintaining your machine or upgrading the technology you have in your manufacturing plant. And so you have bottlenecks emerge because these drugs are cheap, and there's not a profit margin. So you get one factory that makes this key drug, and if that factory hasn't had an upgrade in their machines in 20 years, and that machine conks out and it takes 6 months to repair or replacement, that is an opportunity for that drug to go into shortage and causes a mad dash for big hospitals to purchase the drug that's available, leaving disparities to get amplified. It's a nightmare when those things happen, and they happen all the time. There are usually dozens, if not hundreds, of drugs in shortage at any given time. And this has been going on for decades. This is something that we do need large, system-wide fixes and that investment in quality, I think, will be a key part. Dr. Monty Pal: Yeah, brilliantly said. And I'll make sure that we actually include those articles on the tagline for this podcast as well. I'll talk to our producer about that as well.  I'm really glad you mentioned the time in your last comment there because I felt like we just started, but in fact, I think we're right at our close here, Jason, unfortunately. So, I could have gone on for a couple more hours with you. I really want to thank you for these absolutely terrific insights and thank you for all your advocacy on behalf of ASCO and oncologists at large. Dr. Jason Westin: Thank you so much for having me. I have enjoyed it. Dr. Monty Pal: Thanks a lot. And many thanks to our listeners too. You can find more information about ASCO's advocacy agenda and activities at asco.org. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks so much. ASCO Advocacy Resources: Get involved in ASCO's Advocacy efforts: ASCO Advocacy Toolkit Crisis of Cancer Drug Shortages: Understanding the Causes and Proposing Sustainable Solutions, JCO Oncology Practice Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:     Dr. Monty Pal   @montypal   Dr. Jason Westin @DrJasonWestin   Follow ASCO on social media:      @ASCO on X     ASCO on Bluesky    ASCO on Facebook      ASCO on LinkedIn      Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Jason Westin: Consulting or Advisory Role: Novartis, Kite/Gilead, Janssen Scientific Affairs, ADC Therapeutics, Bristol-Myers Squibb/Celgene/Juno, AstraZeneca, Genentech/Roche, Abbvie, MorphoSys/Incyte, Seattle Genetics, Abbvie, Chugai Pharma, Regeneron, Nurix, Genmab, Allogene Therapeutics, Lyell Immunopharma Research Funding: Janssen, Novartis, Bristol-Myers Squibb, AstraZeneca, MorphoSys/Incyte, Genentech/Roche, Allogene Therapeutics

 In this week's episode, Blood editor Dr. James Griffin speaks with Drs. Emanuele Zucca and Sandra Pinho about their latest articles published in Blood. Dr. Zucca discusses his second analysis of the IELSG37 trial, where findings suggested that R-CHOP21 rituximab, cyclophosphamide,doxorubicin, vincristine, and prednisone, administered every 21 days) may be a suboptimal frontline regimen for PMBCL. Dr. Pinho discusses the aging megakaryocytic niche and its influence on the age-associated decline in HSC and progenitor cell function. The authors demonstrate that remodeling of the megakaryocytic niche and associated platelet factor 4 (PF4) downregulation are central mechanisms driving HSC aging.Featured Articles: Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial Platelet Factor 4 (PF4) Regulates Hematopoietic Stem Cell Aging 

We grant our third Christmas Wish to Tiffany, whose husband Derrick has been dealing with heart issues for years and has recently been diagnosed with Lymphoma. Thanks to Treasure Island Resort & Casino and Holiday Station Stores. DONATE to Christmas Wish: www.kdwb.com/wish.See omnystudio.com/listener for privacy information.

In today's episode, we had the pleasure of speaking with Sarah Rutherford, MD, about the evolving role of minimal residual disease (MRD) and circulating tumor DNA (ctDNA) testing for lymphoma treatment decision-making. Dr Rutherford is an associate professor of clinical medicine in the Division of Hematology/Oncology at Weill Cornell Medicine in New York, New York.  In our exclusive interview, Dr Rutherford discussed the usefulness of ctDNA for guiding patient treatment, clinical trials that are ongoing to determine the best use of this type of assay, how personalized ctDNA testing offers the potential for disease surveillance and effective intervention, key hurdles in the way of widespread implementation of ctDNA testing in clinical practice, and how integration with next-generation sequencing is expected to further tailor treatment strategies.

Today's guest is Erin Cummings, co-founder and executive director of Hodgkin's International, a non-profit dedicated to supporting, educating, and advocating for long-term survivors of Hodgkin's Lymphoma Worldwide. She herself is an over 50 year survivor of Hodgkin's Lymphoma. Erin believes that survivorship is not the end of the cancer journey, but a lifelong chapter that deserves understanding, resources and hope.We talk all about Hodgkin's Lymphoma, treatments that are thankfully no longer in practice, what are called "late effects" of those treatments, the importance of survivorship care and community, pro-active health management, and so much more!!Resources:Erin's Website: https://www.hodgkinsinternational.com/Erin's Facebook:  https://www.facebook.com/hodgkinsurvivorsErin's Linkedin: https://www.linkedin.com/company/hodgkins-internationalErin's Instagram: https://www.instagram.com/hodgkinsinternational/Erin's Email: erincummings@hodgkinsinternational.orgFollow:Follow me: https://www.instagram.com/melissagrosboll/My website: https://melissagrosboll.comEmail me: drmelissagrosboll@gmail.com

In this week's episode, Blood editor Dr. Laurie Sehn interviews authors Drs. Lorenzo Falchi and Robert Levy on their latest papers published in Blood Journal. Dr. Falchi discusses his work on an open-label, multicenter phase 1b/2 study evaluating fixed-duration epcoritamab with rituximab and lenalidomide in 108 patients with relapsed or refractory follicular lymphoma. Dr. Levy shares his work on demonstrating that in vivo expansion of Tregs in recipients prior to transplant is possible by activating TNFRSF25 (also known as death receptor 3) in combination with low-dose interleukin-2 in preclinical models. Both papers showed impressive and promising results for the treatment of lymphoma and GVHD.Featured ArticlesFixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular LymphomaPre-transplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues ameliorating GVHD post-HSCT

Please visit answersincme.com/CAZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology answers the most commonly asked questions from clinicians about the management of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) with antibody–drug conjugates (ADCs). Upon completion of this activity, participants should be better able to: Identify patients with R/R DLBCL who may benefit from ADC therapy in the third-line or later setting; Interpret current evidence to inform selection of ADC therapies for patients with R/R DLBCL in the third-line or later setting; and Discuss strategies to optimize the use of ADC therapies for patients with R/R DLBCL, particularly in the community setting.

Ever wondered what happens when you take the leadership lessons from flying military helicopters and apply them to corporate America? In this conversation with Carl Sharperson Jr., author of "Sharp Leadership" and former Marine Corps pilot, Cam and Otis explore the fascinating transition from military service to business leadership."The plant ran better with us not being there than it did when we were there," Carl reveals, sharing a powerful story about what happened when all the managers went on a two-day retreat. This counterintuitive insight highlights one of Carl's core leadership principles: when you truly empower your people with the right tools and resources, they'll often exceed your expectations.What makes this episode particularly valuable is Carl's candid reflection on his own leadership journey. "My team leader pulled me aside one day and said, 'Carl, you're micromanaging, you don't need to do that,'" he shares, explaining how this direct feedback helped him "flip the script" and transform his approach. From discussing the delicate balance of allowing people to fail without catastrophic consequences to exploring how he applied leadership principles as an entrepreneur, Carl offers practical wisdom drawn from his unique experience across military, corporate, and entrepreneurial settings.Whether you're transitioning from one leadership context to another or simply looking to elevate your team from mediocrity to excellence, Carl's insights on building relationships and taking care of your people provide a roadmap for authentic, effective leadership.More About Carl:Carl Sharperson Jr. is a renowned Leadership Innovation Strategist, speaker, and coach, celebrated for his ability to elevate leaders from mediocrity to their fullest potential in both professional and personal realms. He is the acclaimed author of Sharp Leadership: Overcome Adversity to Lead with Authenticity and Sharp Leadership: Parenting Principles for Rearing Young People. Carl's expertise lies in recognizing that many individuals operate at only 50% capacity due to inadequate leadership, development, or job fit. Through his proprietary Sharp Leadership coaching process, combined with his rich experiences in the military, corporate America, and entrepreneurship, Carl delivers transformative results for his audiences and corporate clients. A proud graduate of the United States Naval Academy and a former United States Marine Corps pilot with a BS in Engineering, Carl has also documented his military experiences in Short Rations for Marines and For My Sons and Brothers. Following his distinguished military service, Carl held senior sales and operational positions at prestigious companies such as Procter & Gamble, Frito-Lay, and Colgate-Palmolive. He was Vice President of Manufacturing for an international sports company before answering the call to entrepreneurship in 2000, launching Sharperson's Executive Leadership. Carl has since worked with executives at major organizations, including Purdue Farms, Harley-Davidson, GlaxoSmithKline, Sara Lee, BMW, Edward Jones, Houston Independent School District, Lockheed Martin, Honeywell, the University of North Carolina, and Chick-fil-A, among others. As a dynamic speaker, Carl travels nationwide, inspiring students to explore military training, sharing his triumphant journey of surviving Stage 4 Non-Hodgkin's Lymphoma and Stage 1 Colon cancer, and empowering leaders with the principles of servant leadership. Dedicated to giving back, Carl actively participates in several community and faith-based initiatives, mentoring youth and helping them reach their maximum potential. He resides in the Upstate of South Carolina with his wife, and they are proud parents of a son and a daughter. If you are ready to elevate your team from mediocrity to excellence, book Carl Sharperson Jr. today.Chapter Times and Titles:From CH-46 to Corporate America [00:00 - 05:00

In this week's episode, Blood editor Dr. Laura Michaelis interviews authors Drs. Terri Parker and Peter Lenting on their latest papers published in Blood Journal. Dr. Lenting discusses his work on introducing a new therapeutic approach to von Willebrand disease with the development of a novel bispecific antibody (KB-V13A12) that links endogenous mouse VWF to albumin, extending VWF half-life twofold with cessation of provoked bleeding. Dr Parker shares the results of a 43-patient phase 2 study that evaluates the single agent isatuximab, a CD38 monoclonal antibody, in patients with relapsed/refractory AL amyloidosis. With a hematological response rate of 77%, organ response rates between 50 and 57%, and an excellent safety profile, the current study lays the foundation for future use of isatuximab across treatment settings and combination strategies.Featured ArticlesIsatuximab for Relapsed and/or Refractory AL Amyloidosis: Results of a Prospective Phase 2 Trial (SWOG S1702)A bispecific nanobody for the treatment of von Willebrand disease type 1

Rugby league great and 2GB favourite, Darryl 'Big Marn' Brohman, has confirmed he's undergoing treatment to address a cancer battle, revealing to Mark Levy he had been diagnosed with Non-Hodgkin's Lymphoma.See omnystudio.com/listener for privacy information.

In this episode of The Top Line, Fierce’s Chris Hayden speaks with Foresight Diagnostics co-founders Dr. Jake Chabon and Dr. Max Diehn about how their company is delivering the next generation of minimal residual disease (MRD) detection in cancer care. Born from research at Stanford University, Foresight’s PhasED-Seq technology delivers ultra-sensitive detection—down to parts per ten million—enabling clinicians to identify microscopic traces of cancer that traditional imaging misses. The discussion explores how Foresight’s MRD platform, CLARITY, can have the ability to support more confident decision-making, from determining curative success in early-stage cancers to guiding consolidation treatment in lymphoma. Chabon and Diehn highlight the company’s biopharma collaborations, clinical trial integration, and evidence-driven approach to guideline inclusion. They also look ahead to a future where MRD testing becomes central to oncology surveillance, accelerating therapy approvals and complementing genomic and digital pathology tools to advance precision medicine.See omnystudio.com/listener for privacy information.

In this episode, two veterinarians, Dr. Natalie Keith and Dr. Josiah Dame discuss lymphoma in dogs (and briefly in cats): common breeds and ages affected, how enlarged lymph nodes present, and the tests used to diagnose (aspiration cytology and PARR). They explain treatment options ranging from steroids and oral drugs to the CHOP chemotherapy protocol, address prognosis differences between B-cell and T-cell lymphoma, and share real clinical stories about rapid progression and difficult decisions. The episode also touches on feline GI lymphoma, the role of routine lab work, and how veterinarians balance diagnostics, treatment costs, and pet quality of life.

In this week's episode, associate editor Dr. James Griffin interviews researchers Dr. John Semple and Dr. Othman Al-Sawaf on their groundbreaking studies on transfusion-related acute lung injury and chronic lymphocytic leukemia treatment. Dr. Semple explored how mitochondrial DNA could act as a first hit in lung injury, while Dr. Al-Sawaf revealed that patient fitness may not significantly impact the efficacy of targeted CLL treatments. Both studies challenge existing medical assumptions and suggest new approaches to understanding disease mechanisms and treatment responses.Featured ArticlesThe impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLLMitochondrial DNA via recipient TLR9 acts as a potent first-hit in murine transfusion-related acute lung injury (TRALI)

 Living and working in the Galapogos, Mollie was living her dream life, but she was concerned about a growing number of health issues. A last-minute decision to go back home to see family ended up saving her life. Within hours of landing in the UK she was in A&E and tests resulted in a diagnosis of diffuse large B-cell lymphoma.  In this podcast, Mollie talks about the struggles of intense chemotherapy, repeated infections, side effects, late effects and fertility. Her lymphoma experience has resulted in a complete change in her life, but one she embraces with the same energy and enthusiasm she has with everything in life. Lymphoma Voices is a series of podcasts for people living with lymphoma, and their family and friends. In each podcast, we are in conversation with an expert in their field, or someone who has been personally affected by lymphoma, who shares their thoughts and experiences. Lymphoma Action is the only charity in the UK dedicated to supporting people affected by lymphoma. We are here to make sure that everyone affected by the condition receives the best possible information, support, treatment and care. Our services include a Freephone helpline, support group network, Buddy Service, medical information, conferences for those affected by lymphoma, and education and training for healthcare professionals. We would like to thank all of our incredible supporters whose generous donations enable us to offer all our essential support services free of charge. As an organisation we do not receive any government or NHS funding and so every penny received is truly valued. From everyone at Lymphoma Action and on behalf of those affected by lymphoma, thank you. For further information visit: www.lymphoma-action.org.uk

In this week's episode, Blood editor Dr. Laura Michaelis interviews author Dr. Taylor Brooks on his latest paper published in volume 146 issue 18 of Blood Journal. The conversation discusses outcomes of bispecific antibodies (epcoritamab or glofitamab) in treating aggressive B-cell lymphoma in a study with 245 patients. Findings show a tentative way forward in treatment for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).Featured Article:Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

On this episode of Bringin' It Backwards, host Adam Lisicky reconnects with Caroline Grace Vein (Blondestandard) for an honest, inspiring conversation about resilience, creativity, and the journey of an artist. Nearly three years after her breakthrough debut "Blue Eyes," Caroline opens up about navigating health challenges—including a diagnosis of Hodgkin's lymphoma just after graduating college—and how they shaped her music and perspective. She shares how those experiences led to a deeper, more authentic songwriting process, the evolution of her sound from bubblegum pop to alternative rock, and the impact of community and collaboration in her work. Caroline dives into the stories behind new singles like "California Dreams," "Freaking Out," "Ruin My Day," and her latest release, "Arms of Another," offering insight into the themes of vulnerability, strength, and connection that drive her artistry. Plus, Caroline reveals she's working on a new podcast to share her story even further, and gives advice to fellow aspiring musicians: stay true to yourself, focus on what you love, and let your art resonate authentically. Whether you're an indie musician, a fan of genuine artist stories, or looking for inspiration to overcome obstacles and pursue your passion, this episode is full of raw, empowering moments you won't want to miss. Listen to the full interview and be sure to subscribe to Bringin' It Backwards for more stories from legendary and rising artists!

Real progress comes when we stop managing symptoms and start understanding the body's messages. What might yours be saying?In this episode, I sit down with Dr. Erin Ellis, a naturopathic doctor whose own health journey from Non-Hodgkin lymphoma to Hashimoto's completely reshaped how she approaches healing. We talk about her path from cancer survivor to women's hormone specialist, and how she uncovered the deeper connections between thyroid autoimmunity, toxins, and genetic vulnerability. Dr. Ellis shares what helped her reverse Hashimoto's antibodies, the foundational steps she teaches her patients, and why true recovery often begins with something as simple as sleep, food quality, and reducing toxic load. Her story is a powerful reminder that the body can heal when we understand why it's reacting, not just how to suppress symptoms.This conversation might help you see your symptoms in a completely new way. Listen now!Episode Timeline: 00:00 – Episode Preview01:20 – Podcast Intro01:44 – Cancer Journey and Motivation02:22 – Why She Focused on Women's Hormones03:40 – The Hashimoto's Diagnosis Story06:16 – Cancer Recurrence and Turning Point14:03 – Hashimoto's Antibodies Turn Negative14:16 – Role of Low-Dose Naltrexone (LDN)15:13 – Gluten, Diet, and Antibody Response16:09 – Oxidative Stress and Glyphosate Link18:43 – Ongoing Detox and IV Glutathione20:31 – Lymphatic Massage and Detox Support24:01 – Sauna, Red Light, and Cold Plunge27:00 – Parasite Cleansing Experience28:24 – Full Thyroid and Hormone Panels30:20 – Starting with Foundational Habits33:35 – Final Advice on Listening to Your Body35:21 – Where to Find Dr. Ellis36:21 – Episode Wrap-Up and Outro36:41 – Dr. Eric's Reflection and TakeawaysAbout Dr. Erin Ellis: Dr. Erin Ellis is a Naturopathic Doctor who helps women balance hormones, improve menstrual health, and regain the energy they once had. After being diagnosed with a rare form of Non-Hodgkin's Lymphoma in 2010, she turned that experience into the motivation to pursue natural medicine. Her journey shaped a mission to help others take control of their health and understand that the body has an innate ability to heal when given the right tools. Life, as she often says, is too short to feel suboptimal. Outside of her work, Dr. Ellis enjoys tim Free resources for your thyroid health Get your FREE Thyroid and Immune Health Restoration Action Points Checklist at SaveMyThyroidChecklist.com High-Quality Nutritional Supplements For Hyperthyroidism and Hashimoto' s Have you checked out my new ThyroSave supplement line? These high-quality supplements can benefit those with hyperthyroidism and Hashimoto's, and you can receive special offers, along with 10% off your first order, by signing up for emails and text messages when you visit ThyroSave.com. Do You Want Help Saving Your Thyroid? Get free access to hundreds of articles and blog posts: https://www.naturalendocrinesolutions.com/articles/all-other-articles Watch Dr. Eric's YouTube channel: https://www.youtube.com/c/NaturalThyroidDoctor/videos Join Dr. Eric's Graves' disease and Hashimoto's group: https://www.facebook.com/groups/saveyourthyroid Take the Thyroid Saving Score Quiz: https://quiz.savemythyroidquiz.com/sf/237dc308 ...

Dr. Hiroto Inaba was raised in a rural province in Japan to honor his samurai heritage. His parents taught him the “Bushido” that an honorable life is one that upholds “the good fight,” Inaba says. After he lost his mother to cancer, he decided his fight would be as an oncologist tackling cancer.

Episode: 2025.11.36The Living Full Out show with Nancy Solari encourages you to take hold of challenges and transform them into opportunities. Maybe you avoid obstacles. Perhaps you need motivation to conquer tough situations. Join Nancy as she discusses taking charge.Our first listener Bob wrote in asking for advice having recently lost his spouse. Losing anyone is tough, but a lifetime partner can be the hardest of them all. Bob seeks answers on how to cope with such a hardship. Tune in to hear as Nancy discusses how to heal this pain. Our second listener Sally wrote in questioning what to do regarding an unbearable work situation. There's untrue gossip going around that is negatively affecting her life. Sally has been breaking out, unable to sleep, and more. Tune in to hear as Nancy discusses what to do to defeat this obstacle. Our inspirational guest Shariann Tom is a five-time cancer survivor. The struggle of being hit by this challenge so many times was undoubtedly difficult. From intense treatment to feeling isolated, she endured. Tune in to hear how Shariann was able to take power and transform her life to be successful and support others.Perhaps you want to prevail over a struggle. Try to lean on a support system that aligns with the challenge you are facing. When you harness adversity, you can feel free and powerful. Then, you'll be living full out. Become a supporter of this podcast: https://www.spreaker.com/podcast/living-full-out-show--1474350/support.

In this Review Series episode, Associate Editor Dr. Philippe Armand speaks with multiple authors about what it might look like to improve treatments follicular lymphoma, a disease that has been put on the backburner of innovation due to its generally treatable nature. Dr. Armand discusses "Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy?" with author Dr. Carla Casulo,  "The future of follicular lymphoma management: strategies on the horizon” with author Dr. Sarah C. Rutherford, and "An updated understanding of follicular lymphoma transformation” with Dr. Erin M. Parry.Find the whole review series on follicular lymphoma in volume 146 issue 15 of Blood Journal.  

Evening prayer (renew us, O Lord, people with lymphoma) #prayer #pray #eveningprayer #jesus #god #holyspirit #aimingforjesus #healing #bible #love #peace #lymphoma #nonhodgkinslymphoma #hodkinslymphoma #renew Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

Hosts Mike Guidone and Chris Caputo welcome Conner Clark to the show to talk top 25 college football. Later, AJ Rovner called in to discuss the good and bad of the Giants game in Denver. Finally, University of Maine punter and native Long Islander Anthony Pecorella discussed his collegiate career and triumph over Lymphoma.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Michael Wang, MD For patients with mantle cell lymphoma (MCL) who relapse after BTK inhibitor (BTKi) therapy, treatment decisions can be complex and time sensitive. That's why understanding how tumor biology and risk features can guide selection between immunomodulatory regimens and CAR T-cell therapy is essential. Tune in to hear Dr. Charles Turck speak with Dr. Michael Wang about practical, evidence-based strategies for managing relapsed/refractory MCL. Dr. Wang is a Professor in the Department of Lymphoma and Myeloma in the Department of Stem Cell Transplantation at MD Anderson Cancer Center in Houston, Texas.

In this week's episode of the Blood Podcast, Associate Editor Dr. James Griffin interviews Drs. Binod Dhakal and Ruben Bierings about their respective papers published in this week's issue of Blood. Dr. Dhakal presents his study on using talquetamab, a bispecific antibody, as a bridging therapy before BCMA-targeted CAR T-cell therapy in multiple myeloma patients, showing promising results with high response rates and manageable toxicities. Next, Dr. Bierings identified patients with genetic variants in the guanine exchange factor MAP kinase–activating death domain (MADD) that impair VWF secretion from endothelial cells and possibly cause VWD type 1. Featured ArticlesA novel cause of type 1 von Willebrand disease: impaired exocytosis of Weibel-Palade bodies due to biallelic MADD variantsSophie Hordijk, Stijn A. Groten, Petra E. Bürgisser, Sebastiaan N. J. Laan, Georg Christoph Korenke, Tomáš Honzík, Diane Beysen, Frank W. G. Leebeek, Paul A. Skehel, Maartje van den Biggelaar, Tom Carter, Ruben BieringsSequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapyBinod Dhakal, Othman S. Akhtar, David Fandrei, Alexandria Jensen, Rahul Banerjee, Darren Pan, Shambavi Richard, Reed Friend, Matthew Rees, Patrick Costello, Mariola Vazquez Martinez, Oren Pasvolsky, Charlotte Wagner, James A. Davis, Omar Castaneda Puglianini, Ran Reshef, Aimaz Afrough, Danai Dima, Manisha Bhutani, Omar Nadeem, Ricardo Parrondo, Ciara Freeman, Lekha Mikkilineni, Shahzad Raza, Larry D. Anderson Jr, Prashant Kapoor, Hitomi Hosoya, Saurabh Chhabra, Ariel Grajales-Cruz, Mahmoud Gaballa, Shonali Midha, Melissa Alsina, Douglas Sborov, Krina Patel, Yi Lin, Christopher Ferreri, Nico Gagelmann, Anupama Kumar, Doris Hansen, Andrew Cowan, Luciano J. Costa, Maximilian Merz, Surbhi Sidana

In this Spotlight series episode on Acute Myeloid Leukemia, Blood Editor, Dr. Selina Luger interviews Drs. Laura Michaelis and Alexander Perl on their paper in the series titled “The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatment”. The conversation explores challenges in treating AML across different patient populations. They also focus on treatment approaches for fit older adults with AML, highlighting the need for less toxic therapies and ongoing randomized trials to better understand treatment efficacy. See the full spotlight series on Acute Myeloid Leukemia in Volume 145 Issue 24 of Blood journal. 

In this week's episode we'll learn more about a study comparing busulfan-melphalan with melphalan alone as the conditioning protocol for newly diagnosed, transplant-eligible multiple myeloma; then we will discuss data on how three-dimensional transcriptomics can reveal complex interactions between plasma cells and bone marrow microenvironments.Featured ArticlesHigh-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trialProfiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomicsPreclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma

In this episode, Meghan Gutierrez, CEO of the Lymphoma Research Foundation, shares insights on how proposed NIH budget cuts could impact cancer research, the importance of stable funding for early-career scientists, and how the foundation is supporting innovation and patient education to accelerate progress against lymphoma.

Cortney Campbell was diagnosed with a rare form of Hodgkin's lymphoma in 2008 at age 26. After a PET scan and other testing she learned it was in her neck, opposite armpit, and small amounts in her rib cage. She had a lymph node biopsied and found that the cancer was slow growing but needed to be addressed because of how much it had spread.  Since the suggested conventional treatment threatened her fertility amongst other permanent side effects, she and her husband opted to pursue non-toxic strategies as a Plan A.  After 8 months of specific anti-cancer diet and lifestyle changes, Cortney was NED and has been ever since. She now has 6 children and leads a community of like-minded cancer thrivers Connect with Cortney@anticancermom on IG and Facebook. You can learn more about her story at AnticCancerMom.com. Resources: Healing Strong Bill Henderson Budwig Protocol Anne Wigmore ___________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com.   To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here.  To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook  Instagram YouTube ____________ Why does Dr. Linda Isaacs, M.D., a board-certified internist, offer an enzyme-based nutritional program for cancer patients? Decades of seeing people have much better outcomes than expected. The approach she uses is not an easy answer and it's not a guarantee. It involves a lot of capsules and big lifestyle changes. But for the right patient, it can be transforming. For more information about her work, please visit her website at www.drlindai.com/radical You can also listen to her interview on the Radical Remission podcast: https://www.podbean.com/ew/pb-7v5kr-1546ad9

Send us a textIn June, the Fatty Liver Foundation officially launched the Stephen A. Harrison Patient Advocacy program and announced its first class of 20 Fellows. In today's conversation, Louise Campbell and Roger Green interview the founders to learn what motivated them to launch this program, and we meet five of the initial Fellows. Program Co-ordinator Elena Samsonova opens the conversation by celebrating last week's onboarding of 20 inaugural Fellows and the chemistry between them. She goes on to introduce five of them:Steven Rodrigues (ALD, UK citizen) shares his recent experience giving a 15-minute national interview on BBC Radio 5 discussing ALD clinical insights. Silvana Lesidrenska (Hepatitis B, Bulgaria) shares her desire to learn more about SLD as part of her advocacy leading a liver patients association in Bulgaria. Julie Peyout (MASH, Canada) is a great-grandmother who was recently found free after therapy for Non-Hodgkin's Lymphoma. Pam Miller (MASH cirrhosis, US) learned 24 years ago that she had MASH cirrhosis when her surgeon aborted a bariatric procedure. Since then, she has lived with cirrhosis and experienced hepatic encephalopathy (HE). She has participated in clinical trials, lobbied legislators, and collaborated with professional societies. Melanie Smith  (MASH cirrhosis, US) has lived with stage-4 MASH cirrhosis since age 36 (sixteen years ago) and experiences hepatic encephalopathy (HE). She has led support groups for over a decade. Next, Fatty Liver Foundation President Wayne Eskridge recounts the program's foundational story. He describes Stephen as a man with a genuine commitment to patients and his passing as a "tremendous loss." This led Wayne to discuss this idea with Rebecca Taub of Madrigal, "another one of my heroes." (Madrigal supports this program.) Elena describes how she joined the FLF to lead this program. Roger asks the Fellows where and how they intend to make a difference. Their goals vary, from working in a Biopharma company advocating for patients to "going to the top," perhaps even lobbying the HHS Secretary, to expanding their own education and knowledge about the various forms of SLD.  

Send us a text00:00:00 - Surf's Up: Season 6 Episode 14Louise Campbell and Roger Green interview key players in the inaugural Dr. Stephen A. Harrison Patient Advocacy Fellowship program, including Wayne Eskridge of the Fatty Liver Foundation (FLF), which initiated the program, Program Coordinator Elena Samsonova, and five Harrison Fellows.00:05:08 - Part I: How the Harrison Fellowship Came To BeElena opens by celebrating last week's onboarding of 20 inaugural Fellows and the chemistry between them. She goes on to introduce five of them:Steven Rodrigues (ALD, UK citizen) shares his recent experience giving a 15-minute national interview on BBC Radio 5 discussing ALD clinical insights. Silvana Lesidrenska (Hepatitis B, Bulgaria) shares her desire to learn more about SLD as part of her advocacy leading a liver patients association in Bulgaria. Julie Peyout (MASH, Canada) is a great-grandmother who was recently found free after therapy for Non-Hodgkin's Lymphoma. Pam Miller (MASH cirrhosis, US) learned 24 years ago that she had MASH cirrhosis when her surgeon aborted a bariatric procedure. Since then, she has lived with cirrhosis and experienced hepatic encephalopathy (HE). She has participated in clinical trials, lobbied legislators, and collaborated with professional societies. Melanie Smith  (MASH cirrhosis, US) has lived with stage-4 MASH cirrhosis since age 36 (sixteen years ago) and experiences hepatic encephalopathy (HE). She has led support groups for over a decade. Next, Wayne recounts the program's foundational story. He describes Stephen as a man with a genuine commitment to patients and his passing as a "tremendous loss." This led Wayne to discuss this idea with Rebecca Taub of Madrigal, "another one of my heroes." (Madrigal supports this program.) Elena describes how she joined the FLF to lead this program. Roger asks the Fellows where and how they intend to make a difference. Their goals vary, from working in a Biopharma company advocating for patients to "going to the top," perhaps even lobbying the HHS Secretary, to expanding their own education and knowledge about the various forms of SLD.  00:34:46 - Part II: Goals of the Harrison Fellowship ProgramThis conversation focuses on the program's goals and scope for its first year. Wayne points out that, while the FLF originally focused on NAFLD and NASH, the new nomenclature has led them to broaden their focus to all forms of SLD. (He plans to rebrand as the Steatotic Liver Foundation.)Elena, it describes the program's four "pillars": Mentorship - Having an experienced advocate guide each Fellow as they pursue the next steps as Advocates.Education - Learning more about SLD.Networking - Connecting with other advocates and industry decision-makers at conferences.Fellowship - Supporting each other as they grow new skills and have new experiences. 00:55:09 - Experts: Louise and Roger Discuss This RoundtableRoger and Louise share their enthusiasm for the unprecedented sense of empowerment they felt among patient advocates while leading this discussion. Both comment on the identity shift from “MASH patient” to “person living with MASH.” Louise mentions that doctors or APPs still minimize disease by characterizing MASLD as “a bit of fat” that requires no action. Roger suggests that focusing on the total patient will include not only the efficacy of medicines but also potential side effects or safety concerns. Louise comments that advanced disease and cirrhosis occur most often in post-menopausal women with cirrhosis, and discusses implications. Both foresee a growing “army” of advocates that can drive earlier detection, smarter trial design, and better everyday care.01:11:11 - Business Report

In this How I Treat podcast episode, Laura Michaelis, MD interviews Sung-Yun Pai, MD about their recently published article in Blood journal "How I treat Wiskott-Alrich syndrome". They highlight recent updates in treatment, including new risk-benefit calculations due to safer treatments and longer follow-ups. Challenges include late diagnosis, lack of well-matched donors, and limited gene therapy availability. They emphasize the importance of early referral to specialized centers and the need for discussions about curative intent therapies, including transplant and gene therapy. The conversation also covers the complexities of gene therapy, such as the need for better conditioning agents and the challenges of achieving full correction in all cell types.

In this week's episode we'll learn about targeting the tissue factor pathway inhibitor with a monoclonal antibody to rebalance HEMOSTASIS in hemophilia A and B. In the phase 3 BASIS trial, the monoclonal antibody marstacimab reduced bleeding events, and was generally well tolerated, with no unanticipated side effects. After that: matched-donor allogeneic CD19 CAR-T for adult B-ALL. Given after allogeneic transplantation, CAR-donor lymphocyte infusion after lymphodepleting chemotherapy was associated with favorable efficacy and a tolerable safety profile. Finally: a new prognostic index for mycosis fungoides and Sézary syndrome. Comprised of four prognostic factors, the “CLIPI” could enable more personalized treatment of cutaneous lymphomas, identifying patients who may benefit from intensified treatment.Featured ArticlesMarstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trialMatched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletionA new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification

Evening Prayer (people with lymphoma, Hodgkin and non-Hodgkin)  #prayer #pray #eveningprayer #jesus #god #holyspirit #aimingforjesus #healing #bible #love #peace #lymphoma #hodgkin #nonhodgkin Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

Today's episode highlights breast health concerns and educates women to make informed choices, as Dr. Robert Whitfield sits down with Dr. Alan Gonzalez, a fellow expert in plastic surgery. They break down what BII is, talk through common symptoms, and dive into complications like capsular contracture and even rare cases of lymphoma. The doctors walk listeners through the different surgical options for removing implants, including total capsulectomy, and discuss alternatives such as fat transfer for those considering a different look after explantation. They don't shy away from discussing the emotional and physical challenges that can come with implant removal, and the conversation is one all women need to hear. Bio: Dr. Alan Gonzalez Dr. Alan González is a leading plastic surgeon in Colombia and Latin America, with over 25 years of experience and more than 20,000 aesthetic and reconstructive procedures performed. Known for combining cutting-edge surgical techniques with a focus on minimal scarring and fast recovery, he is dedicated to enhancing patient well-being through thoughtful, results-driven care. Dr. González is also a global speaker, researcher, and media contributor, and currently leads multidisciplinary research on the link between breast implants and ASIA syndrome. He is affiliated with several international surgical societies and serves as the scientific director of Care Me 360 Institute. (https://careme360.com/) Learn more about Dr. González at dralangonzalez.com (https://dralangonzalez.com/)and connect with him on Instagram (https://www.instagram.com/dralangonzalez/) or LinkedIn (https://www.linkedin.com/in/alan-gonzalez-md/). Show Highlights: Dr. Gonzalez's Background & Early Experience (00:01:09) Dr. Gonzalez shares his medical background, early views on implants, and initial belief in their safety. Recognition of Implant Complications (00:04:25) *Discovering complications like lymphoma, chronic inflammation, and the shift in understanding implant risks *Capsular Contracture & Surgical Approaches (00:10:11) *Capsular contracture, historical surgical practices, and the evolution of implant placement techniques *Patient Symptoms & Chronic Inflammation (00:14:11) Normalization of symptoms, and the importance of recognizing chronic inflammation from implants Capsulectomy Techniques & Cancer Concerns (00:17:26) Debate on total vs. en bloc capsulectomy, surgical safety, and handling abnormal capsule findings Case Study: Lymphoma & Pathology Challenges (00:19:53) Dr. Whitfield shares a case of rare lymphoma, challenges in diagnosis, and the importance of surgical expertise Patient Education & Informed Choices (00:25:47) Educating patients, the need for transparency, and the importance of understanding all surgical options *Alternatives to Implants: Fat Transfer & Lifts (00:27:20) *Non-implant options like fat transfer and breast lifts, and the importance of individualized patient care *Surgeon Expertise & Surgical Evolution (00:44:07) *Importance of expert surgeons, reconstructive techniques without implants, and the evolution of breast surgery Links and Resources Let's Connect Podcast: https://podcasts.apple.com/gb/podcast/breast-implant-illness/id1678143554 Spotify: https://open.spotify.com/show/1SPDripbluZKYsC0rwrBdb?si=23ea2cd9f6734667 TikTok: https://www.tiktok.com/@drrobertwhitfield?t=8oQyjO25X5i&r=1 IG: https://www.instagram.com/breastimplantillnessexpert/ FB: https://www.facebook.com/DrRobertWhitfield Linkedin: https://www.linkedin.com/in/dr-robert-whitfield-md-50775b10/ X: https://x.com/rob_whitfieldmd Read this article - https://www.breastcancer.org/treatment/surgery/breast-reconstruction/types/implant-reconstruction/illness/breast-implant-illness Shop: https://drrobssolutions.com SHARP: https://www.harp.health NVISN Labs - https://nvisnlabs.com/ Get access to Dr. Rob's Favorite Products below: Danger Coffee - Use our link for mold free coffee - https://dangercoffee.com/pages/mold-free-coffee?ref=ztvhyjg JASPR Air Purifier - Use code DRROB for the Jaspr Air Purifier - https://jaspr.co/ Echo Water - Get high quality water with our code DRROB10 - https://echowater.com/ BallancerPro - Use code DRROBVIP for the world's leader in lymphatic drainage technology - https://ballancerpro.com Ultrahuman - Use code WHITFIELD10 for the most accurate wearable - https://www.ultrahuman.com/ring/buy/us/?affiliateCode=drwhitfield

In this week's episode, we'll learn more about relationships between Epstein-Barr virus genomic variants and human diseases, including hematological malignancies; the presence and timing of somatic GATA1 mutations and their relationship to a Down syndrome-specific form of leukemia; and new definitions for high-risk multiple myeloma that emphasize the presence of two or more high-risk cytogenetic abnormalities.Featured Articles:Association of Epstein-Barr virus genomic alterations with human pathologiesClinical significance of preleukemic somatic GATA1 mutations in children with Down syndromeBiallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

Dr. Jonathan Sessler, Professor of Chemistry at The University of Texas at Austin, is no stranger to taking an active role in directing his own path. Being a three-time Hodgkin's Lymphoma cancer survivor, Dr. Sessler's battle with cancer inspired him to research porphyrins, a class of pigments which are essential for biological processes like oxygen transport. On this exciting episode of Let's Talk Chemistry edited by Jasmine Winter, hosts Neel Youts and Jason Lu discuss our interview with Dr. Jonathan Sessler, from unique upbringing growing up in a family of scientists to his pioneering work on creating expanded porphyrins called texaphyrins and co-founding Pharmacyclics, a successful biopharmaceutical company primarily focused on the development of cancer therapies. We hope you enjoy!

Heather Brooker hosts your Friday morning Wake Up Call. Former counterterrorism coordinator for DHS and current ABC News consultant John Cohen opens the show talking about political violence and why it's a ‘both sides' problem. The House Whisperer Dean Sharp joins the show to talk about proposed ‘zero zero' rules and why they are becoming a hot topic in California. Bloomberg Media's Courtney Donohoe shares the latest in business and Wall Street.

Millions of Americans are part of the Sandwich Generation, people who are raising children while also caring for aging parents. For KFI's Heather Brooker, that role became deeply personal when her mother, Barbara, faced lymphoma not once, but twice. For National Blood Cancer Awareness Month, Heather shares her family's story of cancer survival, resilience, and the everyday challenges of balancing life in the middle. With insights from a City of Hope oncologist and a family therapist, this conversation sheds light on the stress, strength, and hope that define the Sandwich Generation.

In this week's episode we'll learn about Azacitidine in VEXAS syndrome. Treatment can provide responses in patients with this complex autoinflammatory disorder. But relapse rates were high, so long-term therapy may be required to maintain disease control. After that: A step forward in precision blood matching. High-throughput array genotyping enables extended matching to reduce antibody formation. The results show the potential for reducing harm in regularly transfused patients. Finally, identifying a new vulnerability in TP53-mutated AML. Loss of the tumor suppressor BAP1 defines a unique subtype of TP53-mutated de novo AML. BAP1 loss also confers sensitivity to BCL-xL inhibitors in vivo, opening a new therapeutic avenue.Featured ArticlesEfficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEXArray genotyping of transfusion-relevant blood cell antigens in 6946 ancestrally diverse study participantsLoss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors

In this Review Series episode, Associate Editor Dr. Hervé Dombret speaks with Dr. Mark Litzow about the latest immunotherapy advances for Acute Lymphoblastic Leukemia (ALL). The discussion highlights innovative treatments like blinatumomab and inotuzumab, which are showing remarkable success in clinical trials, including an 85% three-year survival rate and over 90% complete remission in elderly patients. Researchers are focusing on reducing chemotherapy intensity, developing personalized treatment approaches, and identifying optimal immunotherapy strategies for different ALL subtypes. The conversation underscores a promising shift towards more targeted, less toxic treatments that could significantly improve patient outcomes across various age groups and disease characteristics. These emerging therapies represent a potential paradigm shift in ALL treatment, offering hope for more effective and less aggressive therapeutic interventions.Read Dr. Litzow's paper “Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia” or find the whole review series on acute lymphoblastic leukemia in volume 145 issue 14 of Blood Journal. 

In this episode of Everyday Oral Surgery, we continue our Heme Series on all things blood-related by discussing lymphomas and multiple myeloma. Joining Dr. Stucki on the podcast again, to share a wealth of knowledge, are Drs. Andrew Jenzer and Maxwell Lloyd. They delve into a discussion on the basics of lymphomas, dissecting the two categories of Hodgkin's and non-Hodgkin lymphoma, and get into the diagnosis and presenting symptoms, stages, risk stratification, and treatments of each category. Next, they touch on what Tumor Lysis Syndrome (TLS) is and dive into a broad discussion on multiple myeloma. Dr. Lloyd breaks down the spectrum of this disease, including the signs and symptoms, testing and diagnostics, and explains that there is no cure for the disease. He also expands on the various treatments and management regimens available. To hear more, including thoughts on how to improve communication between collaborating teams, be sure not to miss out on today's episode. Thanks for tuning in!Key Points From This Episode:Introduction to today's topic as we continue our Heme Series.Dr. Lloyd talks us through lymphoma basics.Dr. Jenzer unpacks the presenting symptoms of the Hodgkin lymphoma category.Stages and risk stratification that constantly evolve: Ann Arbor Staging System. Treatment of lymphoma: thinking broadly, as regimens seem to be changing quickly.  We discuss the same aspects, but of the non-Hodgkin lymphoma category.Dr. Lloyd dives broadly into the chemotherapy regimen options for non-Hodgkin lymphoma.He explains a double-hit lymphoma and the associated treatment.We discuss Tumor Lysis Syndrome (TLS).Dr. Jenzer explains what multiple myelomas are. Dr. Lloyd further unpacks the spectrum of this disease (multiple myeloma).Signs and symptoms of multiple myeloma.An explanation for the lack of a cure for multiple myeloma.Testing and diagnostics of multiple myelomaDr. Lloyd broadly delves into the different types of medications and treatments used in managing multiple myeloma.He touches on some of the side effects of the medications.Big takeaway points from today's discussion.Dr. Lloyd's thoughts on how we can improve communication between collaborating teams.Final thoughts and recommendations to listeners.Links Mentioned in Today's Episode:Dr. Andrew Jenzer Email — andrew.jenzer@duke.edu Dr. Maxwell Lloyd — https://connects.catalyst.harvard.edu/Profiles/display/Person/192727 AAOMS — https://aaoms.org/education-meetings/meetings/ NCCN Guidelines — https://www.nccn.org/guidelines/category_1 Ann Arbor Staging System — https://www.ncbi.nlm.nih.gov/books/NBK65726.23/table/CDR0000062933__557/?report=objectonly St. Louis Course — https://stlomfsreview.com/ Everyday Oral Surgery Website — https://www.everydayoralsurgery.com/ Everyday Oral Surgery on Instagram — https://www.instagram.com/everydayoralsurgery/ Everyday Oral Surgery on Facebook — https://www.facebook.com/EverydayOralSurgery/Dr. Grant Stucki Email — grantstucki@gmail.comDr. Grant Stucki Phone — 720-441-6059

In this week's episode we'll learn about persistent changes in immune profiles in patients who have had diffuse large B-cell lymphoma, or DLBCL, and other cancers; that plasminogen activation and plasmin activity do not appear to play a role in routine physiological prevention of venous thromboembolism, or VTE; and about a novel mechanism that makes hematological malignancies carrying epigenetic mutations susceptible to PARP inhibitors.Featured Articles:Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatmentPlasminogen activation and plasmin activity are not required to prevent venous thrombosis/thromboembolismTransposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer

In this week's episode, we'll learn about how TET2 is often mutated in myeloid malignancies and clonal hematopoiesis. In new work, expansion of Tet2-mutant HSPCs was dependent on Ncoa4, the cargo receptor mediating ferritinophagy. We'll iron out the implications. After that: a double-oh-seven license to kill in T-cell leukemia/lymphoma. WU-CART-007 is an off-the-shelf CAR T product with manageable safety and encouraging efficacy. With further work, it could become a new option for patients in urgent need of therapy. Finally: a comprehensive genetic study of classical Hodgkin lymphoma using circulating tumor DNA. This new research provides novel and complex insights on genetic subtypes, prognostic biomarkers, neoantigens in the disease environment, and more.Featured Articles:An in vivo barcoded CRISPR-Cas9 screen identifies Ncoa4-mediated ferritinophagy as a dependence in Tet2-deficient hematopoiesisPhase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignanciesA comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA

To the people who read her blog and attended her church, Amanda C. Riley was a beautiful, young wife and mother who managed to live her life with hope and faith even as she was dying of Hodgkin's Lymphoma. But who was the real Amanda?  The story of how this beguiling woman deceived and betrayed countless supporters, including many of her closest friends, is so compelling, Charlie Webster's 2023 “Scamanda” was the most downloaded and shared podcast, world-wide, on Apple that year, since sparking a 2025 Hulu docuseries. In Part 1 of this fascinating podcast, we first introduce you to the carefully-crafted persona Amanda showed to the world, then take you behind the scenes to meet the real Amanda C. Riley. Join us as we walk through the events that led to one of the most infamous and morally unethical scams ever documented… and ultimately resulted in a first-ever case of its kind for the FBI.  Listen (and follow!) on your favorite app or Scandal Water Podcast YouTube channel.  Thank you to listener Rebekah for her ongoing support on Buymeacoffee.com!   How to support Scandal Water: Rate, review and subscribe! Send your shoutouts to scandalwaterpodcast@gmail.com. Become a member on patreon.com/ScandalWaterPodcast or buymeacoffee.com/scandalwaterpod – which will also grant you access to fabulous bonus content! #Scamanda #Scam #ScammySeptember #TeamAmanda #AmandaCRiley #HodgkinsLymphoma CharlieWebster #Podcaster #Podcast #HuluDocumentary #Season5 #ScandalWaterPodcast 

In this episode of Blood Cancer Talks, we have Dr. Adrian Minson from the Peter MacCallum Cancer Centre to discuss the latest developments in lymphoma presented at the recent EHA and ICML meetings in June 2025. The episode focuses primarily on the emerging role of bispecific antibodies in various combinations and treatment settings for diffuse large B-cell lymphoma (DLBCL).Key Clinical Trials Discussed1. POLARGO Trial - Polatuzumab + R-GemOx vs R-GemOx in R/R DLBCL2. SUNMO Trial - Mosunetuzumab + Polatuzumab vs R-GemOx in R/R DLBCL3. STARGLO Trial - Glofitamab + GemOx vs R-GemOx in R/R DLBCL (2-Year Update)4. EPCORE NHL-5 & NHL-7 - Epcoritamab Combinations in Frontline DLBCL5. EPCOR-RICE - Epcoritamab + R-ICE in Transplant-Eligible R/R DLBCL6. LOTIS-7 Trial - Loncastuximab + Glofitamab in R/R DLBCL7. Additional Studies Mentioned:R-Pola-Glo Frail StudyDLBCL Classification

Our guest this week is another hardcore Huntington Beach OG. A former pro snowboarder turned entrepreneur, he's had an impressive run across multiple industries over the past 20 years. From working as a physical therapist to repping for O'Neill Snow, his hustle never stopped. In 2004, after his cousin Brandon McGuinness (RIP) was diagnosed with Hodgkin's Lymphoma, he co-founded the F C Cancer Foundation—a 501(c)(3) nonprofit focused on early detection and prevention. As Executive Director and CEO, he's dedicated his life to pushing the Foundation's mission forward. We're stoked to hear about his journey, the legacy he's building, and the future he's shaping. Please welcome to the show, Mr. John "MUGS" McGuinness.